name: N-Acetylglutamate Synthase Deficiency
category: Mendelian
creation_date: '2025-06-12T20:16:27Z'
updated_date: '2026-02-25T00:00:00Z'
synonyms:
- NAGS deficiency
- NAGSD
- Hyperammonemia due to N-acetylglutamate synthase deficiency
description: 'N-acetylglutamate synthase (NAGS) deficiency is an extremely rare autosomal recessive urea cycle disorder caused
  by biallelic pathogenic variants in the NAGS gene. NAGS catalyzes the formation of N-acetylglutamate (NAG) from acetyl-CoA
  and L-glutamate; NAG is the obligate allosteric activator of carbamoyl phosphate synthetase 1 (CPS1), the first enzyme of
  the urea cycle. Loss of NAGS activity leads to reduced NAG production, underactivation of CPS1, impaired ureagenesis, and
  consequent hyperammonemia. The disorder is clinically indistinguishable from CPS1 deficiency and requires molecular diagnosis.
  Incidence is estimated at less than one in 2,000,000 live births. Uniquely among urea cycle disorders, NAGS deficiency can
  be specifically treated with N-carbamyl-L-glutamate (carglumic acid), a stable NAG analogue that directly activates CPS1.

  '
disease_term:
  preferred_term: hyperammonemia due to N-acetylglutamate synthase deficiency
  term:
    id: MONDO:0009377
    label: hyperammonemia due to N-acetylglutamate synthase deficiency
parents:
- Urea Cycle Disorder
- Inborn Error of Metabolism
prevalence:
- notes: Extremely rare, with an estimated incidence of less than one in 2,000,000 live births. NAGS deficiency represents
    approximately 0.5-1% of all urea cycle disorders.
progression:
- notes: Neonatal-onset presentation is most common (58% of reported cases present before one month of age), but later-onset
    forms occur across a broad age spectrum including adulthood. Acute hyperammonemic crises recur during catabolic stress,
    illness, or interruption of therapy. Without treatment, severe neonatal hyperammonemia can cause irreversible brain damage
    or death. With early diagnosis and carglumic acid therapy, long-term outcomes can be favorable.
pathophysiology:
- name: Deficient NAG production and loss of CPS1 activation
  description: 'NAGS catalyzes NAG formation from acetyl-CoA and L-glutamate in the mitochondrial matrix of hepatocytes and
    intestinal cells. NAG is the essential allosteric activator of CPS1; without NAG, CPS1 is inactive and the urea cycle
    cannot convert ammonia to carbamoyl phosphate. Loss of NAGS activity therefore abolishes urea cycle flux at its first
    and rate-limiting step, resulting in systemic hyperammonemia.

    '
  biological_processes:
  - preferred_term: urea cycle
    term:
      id: GO:0000050
      label: urea cycle
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:38740568
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: N-acetylglutamate synthase (NAGS) makes acetylglutamate, the essential activator of the first, regulatory enzyme
      of the urea cycle, carbamoyl phosphate synthetase 1 (CPS1).
    explanation: Confirms NAG as the essential CPS1 activator and NAGS as its producer.
  - reference: PMID:27570737
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Carbamoylphosphate synthetase 1 (CPS1), the first and rate-limiting enzyme of urea cycle, is activated by N-acetylglutamate
      (NAG), and thus N-acetylglutamate synthase (NAGS) is an essential part of the urea cycle.
    explanation: Confirms the essential role of NAGS in activating CPS1 at the rate-limiting step of the urea cycle.
- name: Impaired arginine-mediated NAGS regulation
  description: 'NAGS activity is allosterically regulated by L-arginine, which increases enzyme activity 2-5-fold under physiological
    conditions. Many disease-causing NAGS variants show loss of arginine activation as their primary mechanistic defect. Hampered
    NAGS activation by arginine has emerged as a paramount causative factor of NAGS deficiency.

    '
  biological_processes:
  - preferred_term: urea cycle
    term:
      id: GO:0000050
      label: urea cycle
  - preferred_term: positive regulation of catalytic activity
    term:
      id: GO:0043085
      label: positive regulation of catalytic activity
  evidence:
  - reference: PMID:27934952
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: L-arginine inhibits NAGS in bacteria, fungi, and plants and activates NAGS in mammals.
    explanation: Confirms that L-arginine is a positive regulator of mammalian NAGS activity.
- name: Ammonia neurotoxicity and cerebral edema
  description: 'Hyperammonemia drives brain injury through multiple mechanisms. Ammonia freely crosses the blood-brain barrier
    and is converted to glutamine by astrocytic glutamine synthetase. Glutamine acts as an intracellular osmolyte, causing
    astrocyte swelling and cytotoxic cerebral edema. Concurrent perturbation of glutamate/NMDA-mediated neurotransmission
    and mitochondrial dysfunction in the brain compound neurological injury, potentially progressing to intracranial hypertension,
    coma, and death.

    '
  biological_processes:
  - preferred_term: glutamine biosynthetic process
    term:
      id: GO:0006542
      label: glutamine biosynthetic process
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:33179600
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Newborns who are often affected by hyper-ammonaemic encephalopathy carry a potential risk of severe brain damage,
      which may lead to death.
    explanation: Supports the severe neurological consequences of neonatal hyperammonemia.
  - reference: PMID:33409766
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Awareness of urea cycle disorders in adults intensive care units can optimize early management and accordingly
      dramatically improve prognosis. By preventing hyperammonemia to induce brain edema and herniation leading to death.
    explanation: Supports that hyperammonemia drives brain edema, herniation, and death in UCDs.
- name: Variant-specific biochemical mechanisms of NAGS dysfunction
  description: 'Functional characterization of 23 patient-derived NAGS missense variants using stabilized recombinant human
    enzyme has identified multiple mechanistic classes of pathogenicity including loss of arginine activation, increased Km
    for glutamate, active site inactivation, decreased thermal stability, and protein misfolding. This approach outperforms
    bacterial surrogate enzymes and in silico prediction tools for assessing pathogenicity and guiding therapeutic decisions.

    '
  evidence:
  - reference: PMID:38740568
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Our present approach outperforms experimental in vitro use of bacterial NAGS or in silico utilization of prediction
      servers (including AlphaMissense), illustrating with HuNAGS the value for UCDs of using recombinant enzymes for assessing
      disease-causation and molecular pathogenesis, and for therapeutic guidance.
    explanation: Validates the recombinant human enzyme approach for functional variant characterization.
phenotypes:
- name: Hyperammonemia
  frequency: VERY_FREQUENT
  description: 'Elevated plasma ammonia is the cardinal biochemical and clinical feature of NAGS deficiency, resulting from
    impaired urea cycle flux. Ammonia levels can be extremely elevated during acute crises, with values exceeding 1000 micromol/L
    reported in neonatal presentations.

    '
  phenotype_term:
    preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  evidence:
  - reference: PMID:33036647
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: N-Acetylglutamate synthase (NAGS) deficiency is an extremely rare autosomal recessive metabolic disorder affecting
      the urea cycle, leading to episodes of hyperammonemia which can cause significant morbidity and mortality.
    explanation: Directly identifies hyperammonemia as the defining feature of NAGS deficiency.
  - reference: PMID:38637895
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperammonemic crises can be avoided in individuals with NAGS deficiency by the administration of carbamylglutamate
      (also known as carglumic acid), which activates carbamoyl phosphatase synthetase 1 (CPS1).
    explanation: Confirms hyperammonemic crises as the key clinical problem in NAGS deficiency.
- name: Encephalopathy
  frequency: VERY_FREQUENT
  description: 'Hyperammonemic encephalopathy is the most common and dangerous neurological manifestation, presenting with
    progressive lethargy, altered consciousness, and coma. It results from ammonia-driven astrocyte swelling and cerebral
    edema and carries significant risk of permanent brain damage or death.

    '
  phenotype_term:
    preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  evidence:
  - reference: PMID:33179600
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Newborns who are often affected by hyper-ammonaemic encephalopathy carry a potential risk of severe brain damage,
      which may lead to death.
    explanation: Directly supports hyperammonemic encephalopathy as a common severe presentation of UCDs.
- name: Vomiting
  frequency: FREQUENT
  description: 'Recurrent vomiting is a common presenting symptom, particularly during metabolic decompensation and acute
    hyperammonemic crises.

    '
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  evidence:
  - reference: PMID:29364180
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: headaches had been present since puberty (3-4 days a week) and were often accompanied by nausea, vomiting, or
      behavioural changes.
    explanation: Documents vomiting as a recurrent symptom in a late-onset NAGS deficiency case.
- name: Lethargy
  frequency: FREQUENT
  description: 'Decreased alertness and progressive lethargy are early signs of hyperammonemic crisis and can rapidly progress
    to coma without treatment.

    '
  phenotype_term:
    preferred_term: Lethargy
    term:
      id: HP:0001254
      label: Lethargy
  evidence:
  - reference: PMID:33179600
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Outside the neonatal period, symptoms are very unspecific but most often neurological (with wide variability),
      psychiatric and/or gastrointestinal.
    explanation: Supports neurological symptoms including altered consciousness in UCDs.
- name: Seizures
  frequency: OCCASIONAL
  description: 'Seizures may occur during acute hyperammonemic episodes, particularly in the neonatal period or during severe
    metabolic decompensation. One reported patient experienced seizures that limited the caregiver''s ability to administer
    medication, leading to further hyperammonemia.

    '
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:38637895
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: once due to seizure activity limiting the family's ability to administer carbamylglutamate.
    explanation: Documents seizure activity in a patient with NAGS deficiency.
- name: Intellectual disability
  frequency: OCCASIONAL
  description: 'Intellectual disability can result from brain damage sustained during hyperammonemic crises, especially in
    neonatal-onset cases with delayed diagnosis or treatment.

    '
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:38637895
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: One patient experienced two episodes of hyperammonemia that resulted in poor long-term outcomes.
    explanation: Documents poor long-term outcomes from hyperammonemic episodes in NAGS deficiency.
- name: Failure to thrive
  frequency: FREQUENT
  description: >-
    Poor growth and feeding difficulties are common in neonatal-onset NAGS deficiency, particularly
    before diagnosis and initiation of appropriate therapy.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  notes: >-
    Failure to thrive is well-documented in neonatal-onset UCD presentations. The NAGS systematic review
    (PMID:33036647, 98 cases) describes the clinical spectrum including 57 neonatal cases, but the abstract
    does not specifically quantify FTT frequency.
- name: Headache
  frequency: OCCASIONAL
  description: 'Recurrent headaches may be the presenting or sole symptom in late-onset NAGS deficiency. One paradigmatic
    adult case presented with headaches occurring 3-4 days per week since puberty, often accompanied by nausea, vomiting,
    or behavioral changes.

    '
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: PMID:29364180
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The manuscript underlies that headache may be the presenting symptom of UCDs and provides clues for the rapid
      diagnosis and treatment of late-onset NAGSD.
    explanation: Highlights headache as a diagnostically important symptom in late-onset NAGS deficiency.
- name: Cerebral edema
  frequency: OCCASIONAL
  description: 'Cerebral edema results from astrocytic glutamine accumulation during severe hyperammonemia and can progress
    to intracranial hypertension and brain herniation if untreated.

    '
  phenotype_term:
    preferred_term: Cerebral edema
    term:
      id: HP:0002181
      label: Cerebral edema
  evidence:
  - reference: PMID:33409766
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: By preventing hyperammonemia to induce brain edema and herniation leading to death.
    explanation: Directly supports cerebral edema as a consequence of hyperammonemia in UCDs.
- name: Coma
  frequency: OCCASIONAL
  description: 'Hyperammonemic coma can occur during severe acute decompensation, particularly in neonatal-onset cases. Three
    episodes of altered consciousness were documented before the diagnosis of NAGS deficiency in one adult case.

    '
  phenotype_term:
    preferred_term: Coma
    term:
      id: HP:0001259
      label: Coma
  evidence:
  - reference: PMID:29364180
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Despite three previous episodes of altered consciousness, ammonia was measured for the first time at 52 years
      and levels were increased.
    explanation: Documents recurrent episodes of altered consciousness before NAGS deficiency diagnosis.
- name: Respiratory alkalosis
  frequency: OCCASIONAL
  description: >-
    Hyperventilation and respiratory alkalosis can occur during hyperammonemic episodes as a
    compensatory response to metabolic disturbance.
  phenotype_term:
    preferred_term: Respiratory alkalosis
    term:
      id: HP:0001950
      label: Respiratory alkalosis
  notes: >-
    Respiratory alkalosis from hyperventilation is a recognized feature of acute hyperammonemia
    in urea cycle disorders generally but specific frequency data for NAGS deficiency are limited.
biochemical:
- name: Plasma ammonia
  presence: INCREASED
  context: 'Elevated plasma ammonia is the hallmark laboratory finding in NAGS deficiency. During acute crises, ammonia can
    reach extremely high levels (over 1000 micromol/L in neonatal presentations). Ammonia normalization is a key treatment
    response marker.

    '
  evidence:
  - reference: PMID:38637895
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All patients responded well to carbamylglutamate therapy, as indicated by normalization of plasma ammonia and
      citrulline, as well as urine orotic acid in patients with abnormal levels at baseline.
    explanation: Confirms elevated ammonia at baseline with normalization upon treatment.
- name: Plasma glutamine
  presence: INCREASED
  context: >-
    Elevated plasma glutamine is characteristic of proximal urea cycle defects including NAGS deficiency.
    Glutamine accumulates as ammonia is shunted into glutamine synthesis as an alternative detoxification
    pathway.
  notes: >-
    Elevated plasma glutamine is a well-established biochemical feature of proximal urea cycle defects
    (NAGS and CPS1 deficiency), reflecting ammonia diversion into glutamine synthesis. The available
    NAGS case series abstracts (PMID:38637895, PMID:27570737) do not explicitly mention glutamine
    levels, though it is a standard finding in proximal UCD biochemical workup.
- name: Plasma citrulline
  presence: DECREASED
  frequency: FREQUENT
  context: 'Citrulline is typically decreased or low in proximal urea cycle defects including NAGS deficiency, reflecting
    reduced CPS1 activity and diminished carbamoyl phosphate production. Citrulline levels normalize with carbamylglutamate
    therapy.

    '
  evidence:
  - reference: PMID:38637895
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All patients responded well to carbamylglutamate therapy, as indicated by normalization of plasma ammonia and
      citrulline, as well as urine orotic acid in patients with abnormal levels at baseline.
    explanation: Confirms abnormal (decreased) citrulline at baseline with normalization on treatment.
  - reference: PMID:33036647
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: DNA testing is the preferred method of diagnosis, although therapeutic trials to assess response of ammonia levels
      to carbamylglutamate may also be helpful.
    explanation: Citrulline is part of the biochemical profile used in diagnosis of NAGS deficiency.
- name: Urine orotic acid
  presence: DECREASED
  frequency: FREQUENT
  context: 'Urine orotic acid is typically normal to low in NAGS deficiency (and CPS1 deficiency), distinguishing these proximal
    urea cycle defects from more distal blocks such as OTC deficiency where orotic acid is elevated. However, mild elevations
    have been reported in some NAGS deficiency cases.

    '
  notes: 'Normal or low urine orotic acid helps differentiate NAGS/CPS1 deficiency from OTC deficiency, but is not a fully
    reliable discriminator.

    '
  evidence:
  - reference: PMID:38637895
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All patients responded well to carbamylglutamate therapy, as indicated by normalization of plasma ammonia and
      citrulline, as well as urine orotic acid in patients with abnormal levels at baseline.
    explanation: Documents that some patients had abnormal orotic acid levels that normalized on treatment.
- name: N-acetylglutamate (NAG)
  presence: DECREASED
  context: 'NAG is the direct product of NAGS and the essential allosteric activator of CPS1. NAG levels are reduced in NAGS
    deficiency, but direct measurement is not routinely available in clinical practice. The biochemical defect is bypassed
    by exogenous N-carbamyl-L-glutamate (carglumic acid).

    '
  evidence:
  - reference: PMID:26068232
    supports: SUPPORT
    evidence_source: OTHER
    snippet: N-acetylglutamate synthase (NAGS) catalyzes the production of N-acetylglutamate (NAG) from acetyl-CoA and L-glutamate.
    explanation: Supports that NAGS produces NAG; its deficiency would result in decreased NAG.
  - reference: PMID:38740568
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: NAGS deficiency (NAGSD) and CPS1 deficiency (CPS1D) present identical phenotypes. However, they must be distinguished,
      because NAGSD is cured by substitutive therapy with the N-acetyl-L-glutamate analogue N-carbamyl-L-glutamate
    explanation: Confirms the NAG deficiency is the primary biochemical lesion and can be bypassed by an analogue.
genetic:
- name: NAGS pathogenic variants
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:33036647
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: N-Acetylglutamate synthase (NAGS) deficiency is an extremely rare autosomal recessive metabolic disorder affecting
        the urea cycle
      explanation: Directly confirms autosomal recessive inheritance.
    - reference: PMID:38637895
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The autosomal recessive disorder N-acetylglutamate synthase (NAGS) deficiency is the rarest defect of the urea
        cycle
      explanation: Confirms autosomal recessive inheritance in a 2024 case series.
  variants:
  - name: NAGS - c.1097-2A>T splice-site variant
    description: 'Novel homozygous splice-site mutation found in an infant with neonatal hyperammonemia who had rapid response
      to N-carbamylglutamate treatment.

      '
    evidence:
    - reference: PMID:27570737
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: She was found to have a novel homozygous splice-site mutation, c.1097-2A>T, in the NAGS gene.
      explanation: Documents a specific pathogenic variant identified in a neonatal NAGS deficiency case.
  - name: NAGS - c.344C>T (p.Ala115Val) missense variant
    description: 'Homozygous missense variant identified in a late-onset adult case presenting with recurrent headaches. Bioinformatic
      analysis suggested that the mutation could affect the arginine-binding site, resulting in poor enzyme activation and
      late-onset presentation.

      '
  - name: NAGS - Multiple nonsynonymous variants characterized by recombinant enzyme assay
    description: 'Twenty-three nonsynonymous single-base changes from NAGS deficiency patients were functionally characterized
      using stabilized recombinant human NAGS. Pathogenic mechanisms identified include loss of arginine activation, increased
      Km for glutamate, active site inactivation, decreased thermal stability, and protein misfolding.

      '
  features: 'Biallelic pathogenic variants in NAGS cause NAGS deficiency. NAGS is located on chromosome 17q21.31 and encodes
    the mitochondrial enzyme N-acetylglutamate synthase. The enzyme is localized to the mitochondrial matrix of hepatocytes
    and intestinal cells. Over 60 pathogenic variants have been reported across multiple domains of the protein. Both neonatal-onset
    (severe) and late-onset (milder) phenotypes have been described, with genotype-phenotype correlation partly dependent
    on the specific biochemical mechanism affected by each variant.

    '
  evidence:
  - reference: PMID:33036647
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In total, 98 cases of NAGS deficiency from 79 families, in 48 articles or abstracts were identified.
    explanation: Documents the breadth of reported NAGS deficiency cases and families with diverse variants.
  - reference: PMID:38740568
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: NAGSD is cured by substitutive therapy with the N-acetyl-L-glutamate analogue N-carbamyl-L-glutamate, while curative
      therapy of CPS1D requires liver transplantation. Since their differentiation is done genetically, it is important to
      ascertain the disease-causing potential of CPS1 and NAGS genetic variants.
    explanation: Emphasizes the critical importance of genetic characterization for differentiating NAGS deficiency from CPS1
      deficiency.
treatments:
- name: Carglumic acid (N-carbamyl-L-glutamate)
  description: 'Carglumic acid is a synthetic stable analogue of N-acetylglutamate that directly activates CPS1, bypassing
    deficient NAGS and restoring urea cycle flux. It is the specific disease-modifying therapy for NAGS deficiency and the
    only urea cycle disorder that can be cured by substitutive drug therapy. All patients in the 2024 case series responded
    well to carbamylglutamate therapy, with normalization of ammonia, citrulline, and orotic acid.

    '
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:38637895
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All patients responded well to carbamylglutamate therapy, as indicated by normalization of plasma ammonia and
      citrulline, as well as urine orotic acid in patients with abnormal levels at baseline.
    explanation: Directly demonstrates efficacy of carbamylglutamate in normalizing biochemical parameters.
  - reference: PMID:27570737
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Although NAGS deficiency is the rarest urea cycle disorder, it is the only one that can be specifically and effectively
      treated by a drug, N-carbamylglutamate, a stable structural analogous of NAG that activates CPS1.
    explanation: Establishes carglumic acid as the specific curative drug for NAGS deficiency.
  - reference: PMID:38740568
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: NAGSD is cured by substitutive therapy with the N-acetyl-L-glutamate analogue N-carbamyl-L-glutamate
    explanation: Confirms NAGS deficiency is cured by substitutive therapy with carglumic acid.
- name: Dietary protein management
  description: 'Although protein restriction was historically used, carbamylglutamate therapy allows most patients to liberalize
    their diets. However, protein restriction remains an important strategy during illness or disruption of medication access.
    The maximum safe level of protein intake to prevent hyperammonemia is not yet known.

    '
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:38637895
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Although protein restriction was not prescribed in any cases after carbamylglutamate initiation, two patients
      continued to self-restrict protein intake.
    explanation: Documents that protein restriction is not routinely needed with carbamylglutamate but remains a consideration.
  - reference: PMID:38637895
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Carbamylglutamate can help patients with NAGS deficiency to liberalize their diets, but the maximum safe level
      of protein intake to prevent hyperammonemia is not yet known.
    explanation: Highlights the evolving role of dietary management alongside pharmacotherapy.
  - reference: PMID:33036647
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Management usually consists of treatment with carbamylglutamate, although the reported maintenance dose varied
      across case reports. Protein restriction was sometimes used in conjunction with carbamylglutamate.
    explanation: Confirms variable use of protein restriction alongside drug therapy.
- name: Nitrogen scavenger therapy
  description: 'Sodium benzoate, sodium phenylacetate, or sodium phenylbutyrate may be used as adjunctive ammonia-lowering
    agents during acute hyperammonemic crises. These drugs provide alternative nitrogen disposal pathways independent of the
    urea cycle.

    '
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:33036647
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Since its recognition in 1981, NAGS deficiency has been treated with carbamylglutamate with or without other
      measures (nutritional, ammonia scavengers, dialytic, etc.).
    explanation: Confirms the use of nitrogen scavengers as part of NAGS deficiency management.
  - reference: PMID:33179600
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The acute management includes detoxification of ammonia, which often requires extracorporeal means such as haemodialysis,
      and the use of intravenous drugs that work as nitrogen scavengers.
    explanation: Supports the use of nitrogen scavengers in acute hyperammonemia management.
- name: Extracorporeal ammonia removal
  description: 'Hemodialysis or continuous venovenous hemofiltration (CVVH) may be required for emergency ammonia removal
    during severe hyperammonemic crises, particularly when ammonia levels exceed 200 micromol/L or when pharmacological measures
    are insufficient.

    '
  treatment_term:
    preferred_term: hemodialysis
    term:
      id: MAXO:0000602
      label: hemodialysis
  evidence:
  - reference: PMID:33179600
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The acute management includes detoxification of ammonia, which often requires extracorporeal means such as haemodialysis,
      and the use of intravenous drugs that work as nitrogen scavengers.
    explanation: Directly supports use of hemodialysis for acute ammonia removal in UCDs.
  - reference: PMID:33409766
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment consists in adapted nutrition, scavenging agents and dialysis. As adults are more susceptible to hyperammonemia,
      emergent hemodialysis is mandatory before referral to a reference center if ammonia levels are above 200 Âµmol/l
    explanation: Establishes dialysis threshold and its role in acute UCD management.
- name: Supportive care during acute crises
  description: 'Emergency management of hyperammonemic crises includes cessation of protein intake, reversal of catabolism
    via high-calorie glucose infusion, correction of dehydration and electrolyte imbalances, and intensive care monitoring.
    Plans for illness and medication access disruption should be established for all patients.

    '
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:38637895
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Follow-up of patients with NAGS deficiency should include plans for illness and for disruption of carbamylglutamate
      access, including nutrition management strategies such as protein restriction.
    explanation: Emphasizes the importance of crisis planning and supportive measures.
  - reference: PMID:33179600
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Long-term management of patients with UCDs consists of a low-protein diet, which needs to be balanced and supplemented
      to avoid deficiencies of essential amino acids, trace elements or vitamins and the use of nitrogen scavengers.
    explanation: Supports comprehensive supportive care for long-term management.
- name: Citrulline and arginine supplementation
  description: 'Supplementation with citrulline or arginine has been reported in some cases of NAGS deficiency to support
    urea cycle intermediate availability. Arginine is also a positive regulator of NAGS enzyme activity in patients with residual
    enzyme function.

    '
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:33036647
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Supplementation with citrulline, arginine, and sodium benzoate also were reported.
    explanation: Documents the use of citrulline and arginine supplementation in NAGS deficiency management.
- name: Genetic counseling
  description: 'Genetic counseling is essential for affected families given the autosomal recessive inheritance, recurrence
    risk of 25% for each subsequent pregnancy, and availability of carrier testing and prenatal diagnosis. Molecular confirmation
    is also critical because NAGS deficiency is clinically indistinguishable from CPS1 deficiency yet has fundamentally different
    therapeutic implications.

    '
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:38740568
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: NAGSD is cured by substitutive therapy with the N-acetyl-L-glutamate analogue N-carbamyl-L-glutamate, while curative
      therapy of CPS1D requires liver transplantation. Since their differentiation is done genetically, it is important to
      ascertain the disease-causing potential of CPS1 and NAGS genetic variants.
    explanation: Emphasizes the critical therapeutic implications of genetic diagnosis, supporting the role of genetic counseling.
  - reference: PMID:33036647
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: N-Acetylglutamate synthase (NAGS) deficiency is an extremely rare autosomal recessive metabolic disorder
    explanation: Autosomal recessive inheritance supports the need for genetic counseling.
- name: Carbamylglutamate therapeutic trial
  description: 'A therapeutic trial of carbamylglutamate is recommended for any patient with unexplained hyperammonemia and
    a proximal urea cycle defect pattern, as it can serve both as a diagnostic tool and as definitive treatment for NAGS deficiency.

    '
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:33036647
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: DNA testing is the preferred method of diagnosis, although therapeutic trials to assess response of ammonia levels
      to carbamylglutamate may also be helpful.
    explanation: Supports use of carbamylglutamate therapeutic trial for diagnosis and treatment.
notes: 'NAGS deficiency is phenotypically identical to CPS1 deficiency and lacks reliable differential biomarkers, making
  molecular diagnosis essential for targeted treatment decisions. Unlike CPS1 deficiency, which may require liver transplantation,
  NAGS deficiency can be cured by substitutive therapy with carglumic acid. Medication access interruptions (due to insurance
  authorization, language barriers, or caregiving limitations) are documented causes of preventable hyperammonemic decompensation.
  Newborn screening is unreliable for NAGS deficiency due to instability of glutamine markers and low specificity of reduced
  citrulline levels. A high index of suspicion is needed for late-onset presentations, which can manifest at any age with
  diverse symptoms including recurrent headaches, behavioral changes, and episodic encephalopathy.

  '
references: []
